Biogen Inc. (BIIB) Earnings Call Transcript & Summary

October 28, 2026

NASDAQ US Health Care Biotechnology earnings 64 min

What were the key takeaways from Biogen Inc.'s October 28, 2026 earnings call?

In the third quarter of 2026, Biogen Inc. reported total revenue of $2.8 billion, reflecting an 11% year-over-year growth, driven significantly by the acquisition of Apellis. The company achieved a core pharmaceutical revenue of $2 billion, up 18% year-over-year, with notable contributions from its growth portfolio, which generated approximately $1.3 billion, marking a 49% increase. Management raised the lower end of its non-GAAP diluted EPS guidance for the full year 2026 to between $12.20 and $13, indicating confidence in sustained growth and improved operational efficiency following the Apellis integration.

What topics did Biogen Inc. cover?

  • Strong Revenue Growth: Biogen achieved total revenue of $2.8 billion in Q3 2026, which is an 11% increase year-over-year. Management highlighted that this growth was significantly aided by the Apellis acquisition, stating, "the integration has gone even better than expected."
  • Growth Portfolio Performance: The growth portfolio generated approximately $1.3 billion in revenue, up 49% year-over-year, representing about 63% of total core pharmaceutical revenue. Management noted, "the growth portfolio has now exceeded the legacy MS portfolio for multiple consecutive quarters."
  • Guidance Update: Biogen raised the lower end of its non-GAAP diluted EPS guidance for 2026 to between $12.20 and $13, reflecting confidence in operational improvements and synergy capture from the Apellis acquisition. Robin Kramer stated, "we have been encouraged by the faster synergy capture from the Apellis acquisition."
  • Pipeline Developments: Management emphasized the strength of their late-stage pipeline, with multiple registrational readouts expected in the coming months. Priya Singhal mentioned, "we expect to continue our multiyear cycle of important registrational data flow through the end of the decade."
  • Integration Success: The integration of Apellis is reportedly ahead of schedule, with management stating that most of the dilution from the acquisition will be from financing rather than operational impacts. Chris Viehbacher noted, "the transaction is now roughly neutral on an operating basis."

What were Biogen Inc.'s October 28, 2026 results?

  • Total Revenue: $2.8 billion (+11% YoY)
  • Core Pharmaceutical Revenue: $2 billion (+18% YoY)
  • SPINRAZA Revenue: $461 million (+23% YoY)
  • SYFOVRE Revenue: $191 million (+27% YoY)
  • Free Cash Flow: $600 million
  • Non-GAAP Diluted EPS Guidance: $12.20 - $13

Biogen's strong Q3 performance, driven by the Apellis acquisition and robust growth portfolio, positions the company favorably for future growth. The raised EPS guidance and pipeline developments are positive catalysts, while the need for effective market education and competitive pressures remain key risks to monitor.

Earnings Call Speaker Segments

Tim Power

executive
#1

Thank you, Cynthia, and good morning to everyone. It's a pleasure to welcome you to Biogen's earnings call for the third quarter of 2026. On this call, we'll be sharing forward-looking statements, and those carry risks and uncertainties that could cause actual results to differ materially from what those statements suggest. A comprehensive list of risk factors appears in our SEC filings, and I'd encourage you to take a look at them. You can find our earnings release and other documents related to our results, along with reconciliations between GAAP and non-GAAP results discussed on this call, in the Investors section of biogen.com. The slide we'll be using during the call has also been posted to our website. Joining me on today's call are our President and Chief Executive Officer, Chris Viehbacher; Dr. Priya Singhal, Head of Development; Robin Kramer, our Chief Financial Officer; and Alisha Alaimo, President, North America, who is also available for the Q&A portion of the call. We'll offer some opening comments, and then we'll move to the Q&A session, and so that we can get to as many questions as possible, we'd ask you to kindly limit yourself to just one question. I'll now hand the call over to Chris.

Christopher Viehbacher

executive
#2

Okay. Thanks, Tim. Morning, everyone. We had a really strong quarter this morning—one of those where the figures kind of tell the story on their own. Our total revenue was up 11% compared with a year earlier. Naturally, not all of that came organically. The Apellis acquisition gave it a significant boost. Still, I'd say the purchase and the integration of Apellis have gone better than we'd anticipated. In my view, the integration team has managed to spot and remove cost synergies more quickly than expected. Alisha is with us, and she deserves a great deal of credit for her leadership and for really making sure the Apellis team has felt welcomed inside Biogen. The real praise, in my view, should go to the Apellis team members who joined Biogen, placed their confidence in us, looked beyond the inevitable turbulence of an integration, and kept their attention squarely on the customers, health care professionals, and patients we serve. So from my vantage point, Apellis has plainly benefited us. Bolt-on acquisitions have long been embraced across our industry. Yet one thing I've come to understand is that a bolt-on only works when there's something sturdy to attach it to. Over the past several years at Biogen, one focus has been reinforcing our cost structure while also genuinely bringing our growth products to market and ensuring they deliver at the highest level. This is important since some disruption is inevitable when you complete an acquisition. When your existing team is already delivering strong results, it not only has room to welcome a new group coming aboard; that incoming group also encounters a culture of vitality and upbeat spirit that tends to spread in certain ways. So I believe we have genuinely realized the synergy between the Apellis colleagues who came into the Biogen teams. They have united. Looking at SYFOVRE and EMPAVELI, those two are growing roughly 30-some percent compared with a year ago and together bring in $243 million. That already represents a $1 billion run rate, and we expect to deliver $250 million in run rate synergies by the close of 2027. As a matter of fact, the guidance we issued—Robin will cover this in more depth—shows we have reduced our projection for dilution during this first year of the acquisition. Actually, the bulk of that dilution stems from the financing. On an operating basis, dilution is essentially negligible at this point. Turning to Biogen's own growth portfolio, it stands at $1.26 billion, which is 50% growth year-over-year. That figure now represents nearly two-thirds of core pharmaceutical revenue for Q3. This is really the heart of the story: our legacy portfolio continues to hold up well, but the future genuinely belongs to the growth products. Turning to the next slide, we have three main priorities. First, continuing to grow the commercial portfolio — and as I noted, 50% growth is exceptionally strong. We also anticipate returning to top-line growth in 2026. I've said this before: the durability of the legacy MS portfolio is no accident. Biogen has a distinctive patient services team. I think we've established solid ties with leading physicians and gained the confidence of many patients. That, in my view, is a capability that will matter enormously as we shift focus to the next priority: a multiyear stream of registrational data. On that, my first point is that, with the Apellis acquisition now behind us, we believe the company can grow even without the pipeline. So as the pipeline begins to report out — and I believe the first readout is only weeks away now — we think we can be launching products; provided the clinical trial results come back positive, we'll be in a position to launch products on top of a growing base. Beyond that, I'd note that several areas remain at the breakthrough stage for us. Take AMR — that market doesn't exist yet. MDI is another market that doesn't exist. A great deal of education is required, in fact, though we're already observing strong awareness around both. We understand how to create and build markets; we're not an organization accustomed merely to entering an established market and capturing share; that capability will matter in lupus as well. Alisha can offer considerably more detail on this. Yet if you examine the lupus market, it's only a portion of the size of the MS market, and there isn't any genuinely solid justification for that. We've uncovered certain insights regarding this. One is that patients are anticipated to remain on therapy for a great many years, and because just 2 biologics have been approved, physicians generally hold those biologics in reserve until a patient's condition worsens. Market feedback has been substantial: should one more biologic secure approval, there'd be greater readiness to employ biologics sooner in the treatment journey. That brings me back to the way Biogen constructed its MS franchise and managed to hold onto it despite rather intense competition. I believe a lot of those capabilities and skills will really allow us to think about how we can truly expand the lupus market well beyond its current level; and over the next 18 months, we expect Phase III readouts not only in SLE but in cutaneous lupus as well; we have AMR, and together with our partners at Stoke, we anticipate reporting on Zorevunersen in < > syndrome; and the third priority, the third area, I think, is one of the most important and often most overlooked parts of our industry; and this is a space where our top leadership at Biogen is investing a great deal of our time. Since a company's future gets built inside research and early development, and that was an area where we honestly weren't strong—three years passed with no IND at all—Jane Grogan, working closely with Priya Singhal, has driven a complete restructuring of that whole organization. Today we expect 6 new programs alongside the 3 NMEs. As Priya will confirm, 5 INDs have already come through this year, and never once in Biogen's 48-year history has the company produced 5 INDs within one year. Looking ahead a few years, our goal is no fewer than 20 programs sitting in early-stage development. This represents a major change in our operating model, since in the past Biogen evaluated things one asset at a time. Today, though, we're genuinely considering opportunity portfolios. How do we balance risk, and how do we balance that against franchise growth and breakthrough therapies together with best-in-class medicines, rather than always only first-in-class ones? That's an area where planning for the future is already underway. In this industry, the moment you launch a new product is the moment you ought to be considering which product will follow it. So those are the three areas. I find it exciting. Biogen's future belongs to us — and on that note, I'll hand things over to Priya, who can share a bit more on the excitement that awaits us.

Priya Singhal

executive
#3

Thanks, Chris, and good morning, everyone. During the last several years, you've heard us discuss how the pipeline has been transformed, as Chris noted a moment ago. I'd like to spend a few minutes reminding all of you where things stand as of today. Our new Biogen strategy is still focused on providing a route toward sustainable growth across the long term, and the progress achieved in pursuit of that objective pleases us; this is an exciting moment for Biogen. And today, thanks to this strategy, we hold 1 of the strongest and most diversified late-stage pipelines in Biogen's history, with the potential to address significant unmet need across neurology, immunology and kidney disease; we presented this slide to you last quarter, and as we communicated previously, because of strong execution by our teams and positive enrollment momentum, we managed to pull forward the TOPAZ-2 SLE readout folitufolumab and the TRANSCEND readout for felzartamab in AMR; so as reflected on the slide, I'm pleased that our upcoming registrational readout cycle remains on track. Beginning with our planned disclosure of the Phase III SLE studies for litufulumab in the first half of December. Turning beyond that, we anticipate CLE data from < > along with AMI data from salzatumab, followed by a readout from ZorumNersen in Ravi syndrome expected in the third quarter of next year. Past that, we expect to keep up our multiyear cycle of important registrational data flow through the end of the decade. Every one of these upcoming catalysts could meaningfully shape Biogen's next phase of growth, while most importantly, opening the possibility of new treatment options for patients. As Chris also noted, we have stayed focused on building and rebuilding our early-stage pipeline. We will keep concentrating on our portfolio construction and assess internal and external innovation on a program-by-program basis with a scientific and disciplined approach. Looking ahead, I'm excited about how our transform pipeline could benefit patients across disease areas, and I look forward to providing updates as we move forward; with that, I would now like to hand the call over to Robin for the financial update. Thank you.

Robin Kramer

executive
#4

Thank you, Priya. I'm happy to share an update on yet another robust quarter of financial results. What we're reporting reflects the momentum our commercial portfolio has maintained all through this year, and Q3 is the first complete quarter that includes SYFOVRE and EMPAVELI within our growth portfolio. Core pharmaceutical revenue for the third quarter totaled $2 billion, which is 18% higher than a year ago and 9% above the prior quarter; the driver was the ongoing strong showing of our growth portfolio, which brought in roughly $1.3 billion of revenue during the quarter, an increase of 49% year-over-year and 19% quarter-over-quarter. On top of that, SYFOVRE and EMPAVELI combined added $243 million in Q3 2026. That portfolio now accounts for about 63% of our total core pharmaceutical revenue; the results this quarter show sustained strong commercial execution and highlight how much progress we've achieved in transitioning our portfolio. Let me walk you through the key highlights from our core pharmaceutical product performance in the third quarter. Starting with the growth portfolio. SPINRAZA revenue came in at $461 million, 23% higher year-over-year and 15% higher quarter-over-quarter; that result was mainly driven by swift patient conversion to the high dose regimen, with the quarter reflecting a meaningful revenue tailwind tied to the onetime transition doses for patients moving from low dose SPINRAZA. As the conversion cohort matures and dosing patterns normalize, particularly in the U.S. We anticipate global Q4 revenue will rise by roughly a mid-single-digit percentage compared with the fourth quarter of 2025. We're pleased with how quickly conversion to high dose has proceeded, which has come in ahead of our expectations. We find the enthusiasm among patient and prescriber communities encouraging for the opportunity for < > revenue was $192 million, down 11% year-over-year and 2% quarter-over-quarter. Revenue this quarter was affected by a shift in the Part D landscape, where payers have taken a tighter approach to formulary management, a broader macro trend visible across the industry; we expect this formulary dynamic to keep affecting Part D drugs such as VUMERITY this year. Consequently, we anticipate fourth quarter revenue from emeriti will be roughly flat sequentially or up approximately a mid-single-digit percentage versus the fourth quarter of 2025. Looking further out, we believe these dynamics establish a new base from which VUMERITY can grow. Lakevi end market revenue was $202 million, up 67% year-over-year, and 10% quarter-over-quarter, as market growth has continued in key geographies. We are in the early stages of the iClick launch and have begun to see some uptake in the U.S. Patients can presently obtain reimbursement for iClick through a medical exception process. We expect uptake will be gated by broader reimbursement, with coverage plans now being finalized; we're encouraged that at least 50% of covered lives are expected to have coverage for both initiation and maintenance administration starting in 2027, which should support iClick adoption as we move into the next year. Skyclaris saw patient demand growth both in the U.S. And outside the U.S., revenue came in at $178 million, which works out to 34% growth versus a year ago and 6% growth over the prior quarter. Our third quarter results also show some favorable inventory dynamics, and that includes an inventory build of roughly $12 million, which we expect will be drawn down during Q4. Turning to our legacy MS portfolio, TYSABRI posted revenue of $437 million, an increase of 1% year-over-year; U.S. revenue got a lift from inventory dynamics compared with a year earlier, while the European business remains stable, supported by the subcutaneous formulation. We've been gratified to see TYSABRI show meaningful resilience given how competitive the MS market is. Now let me move on to SYFOVRE and EMPAVELI. Q3 was the first full quarter of operations since the Apellis acquisition closed in May, and integration keeps moving along nicely, with both SYFOVRE and EMPAVELI delivering another strong quarter. SYFOVRE revenue reached $191 million, up 27% year-over-year, powered by ongoing growth in commercial injection volume, which rose 18% year-over-year and 7% quarter-over-quarter. This third quarter was our strongest for commercial injections since launch, and SYFOVRE keeps showing market leadership and geographic atrophy. I'd point out that third quarter results include an inventory build of about $11 million, which we expect to be drawn down in Q4. As we look ahead to Q4, we also anticipate that our price will normalize back to historic levels after a onetime price benefit tied to the co-pack launch. Even so, we expect fourth quarter revenue to rise by roughly a mid-single-digit percentage compared with the $155 million Apellis reported in the fourth quarter of 2025. At EMPAVELI, revenue was $52 million, an increase of 11% quarter-over-quarter, driven by strong demand in the nephrology indications, C3G and primary IC-MPGN. Sequential demand for PNH remains stable, and since this market is highly competitive, we are hiring a dedicated sales force to drive PNH penetration. Given this commercial performance and the pace at which we're capturing integration synergies, we believe the transaction is now roughly neutral on an operating basis, and we expect it to be less dilutive in 2026. We still expect the transaction to be accretive to non-GAAP diluted EPS in 2027, generating at least $250 million of run rate synergies by the end of 2027. Now I'll turn to the financial highlights for the quarter. Total revenue was $2.8 billion, up 11% year-over-year. That marks an acceleration in our top line growth trajectory, helped by the impact of the Apellis acquisition on our overall revenue profile. Non-GAAP core OpEx, or combined R&D and SG&A expense, increased 27% year-over-year; this increase mainly reflects the expected impact of Appellate operating expenses as well as continued investment in our Phase III programs, < >, felzartamab in AMR, < > syndrome and salinersen and SMA, along with support for the U.S. and international product launches and prelaunch activities for our late-stage pipeline assets. Like we said before, in Q3 2026 we booked $284 million in acquired IPR&D plus milestone charges, mostly tied to our Rather acquisition; that works out to roughly a $1.70 hit to non-GAAP diluted EPS and about a $1.65 hit to GAAP diluted EPS. GAAP EPS came in as a loss of $0.14, driven by the IPR&D and milestone charges I mentioned, along with higher amortization costs from the acquired inventory fair value step-up adjustment for < > stemming from the Riata transaction and SYFOVRE the EMPAVELI from the Apellis transaction, plus restructuring costs tied to the Apellis acquisition. Moving now to cash flow and the balance sheet. We're still producing robust cash flow, with $600 million of free cash flow in the third quarter of 2026. We closed the quarter holding $1.3 billion in cash and $6.4 billion of net debt. In Q3, we paid down $400 million of the term loans connected to the Apellis acquisition. That brings total repayment to $600 million, and we still expect to retire the remaining $1.4 billion of term loans by the end of 2027. Shifting to guidance. As you heard this morning, business momentum stayed solid through the third quarter and, importantly, we remain on track to deliver top line growth for the first time in several years. Faster-than-expected synergy capture from the Apellis acquisition has been encouraging, producing favorability in the expected 2026 dilution.

Robin Kramer

executive
#5

We're happy to be lifting the bottom of our reported full year 2026 non-GAAP diluted EPS range, so it now sits between $12.20 and $13. Results in the third quarter also show the strength of our execution, and that includes revenue accelerating thanks to the faster pace of conversion from the high dose regimen of SPINRAZA in Q3. On top of that, we anticipate a degree of typical Q4 phasing, along with the SKYCLARYS inventory dynamics that I mentioned a few moments ago, and we still expect contract manufacturing revenue to be lower in the fourth quarter because of the timing of batch commitments. Thinking about where we stand today on core operating expenses, we're pleased that some of the appellate synergies have been captured more quickly than we anticipated. Our Core OpEx guidance reflects the usual seasonal increase in core OpEx spending during the fourth quarter and includes the planned investments needed to support progress on our late-stage pipeline and our prelaunch activities. We also now accept approximately $50 million of acquired IP R&D in the fourth quarter. We'll keep balancing that investment, as well as the investment made to support commercial success for the growth portfolio, while making sure a keen focus stays on profitability. Please make sure you review this slide, and also our press release, for the other important full year 2026 guidance assumptions. To close, Q3 2026 was another strong quarter and a continuation of the momentum we've seen throughout this year. Our growth portfolio has now surpassed the legacy MS portfolio for several consecutive quarters, and the first full quarter of SYFOVRE and EMPAVELI shows the strategic and financial rationale behind the Apellis acquisition. As we've strengthened our portfolio, we're on track to grow the business next year, and we're also focused on important data reads from our pipeline that will further strengthen our long-term growth potential. With that, I'd like to hand the call back to Tim so we can open it up for questions.

Tim Power

executive
#6

Thanks, Robin. Can we go to the first question, please, Cynthia.

Phil Nadeau

analyst
#7

Nice quarter—congratulations on that. I'd like to ask about the linafilumab data coming up in SE. It feels like investors are starting to focus on that now. Could hydrogen talk about how confident it is that those Phase III trials will succeed, and maybe fold in how the Phase III design differs from Phase II?

Christopher Viehbacher

executive
#8

Priya, would you like to handle that one?

Priya Singhal

executive
#9

Apologies, and thank you, Phil. So, taking a step back, we do recognize and acknowledge that lupus is a highly heterogeneous disease. We’ve examined previous trials — and we have extensively implemented multiple strategies in order to optimize the outcomes. I’ve talked about those before; and just to name a few. The steroid tapering, control of background standard of care meds. So there isn’t really anything new that I can add regarding those strategies. We remain very close now with both of them being disclosed in the first part of — first half of December; so I’ll just stop here and we look forward to seeing the data as well.

Chris Schott

analyst
#10

I just have a question about fulzartinab. I realize you touched on this somewhat in your opening remarks, but if the AMR data come back positive, could you discuss a little how you're viewing the pace of market development and how the product will ramp? And again, perhaps just to dwell on this market a bit more. Maybe just comment a little on how — the Street is modeling this? And do you believe the Street is more or less getting it right regarding how large an opportunity this might be.

Alisha Alaimo

executive
#11

Chris, it's Alisha here, and I'll take that question. We've been devoting considerable time to examining AMR, and I think we've also been looking closely at MVI, which I'll mention briefly. But regarding AMR, and in fact just recently at ASN, the team genuinely spoke with a large number of the transplant physicians who would potentially be treating patients for this disease; and I must say they were highly enthusiastic about the science of the MOA. And those conversations really were incredibly positive. With AMR, we estimate there are roughly 11,000 patients, and you also need to keep in mind that not every one of those patients will end up on products — several of them will already be too far along in their progression — but there is a very sizable cohort that will. Right now, AMR is treated at transplant centers, and transplant centers view themselves as stewards of the graft. So what's interesting about this space is that we know precisely who will be treating the patients. It comes down to getting the patients in there. The 1 thing we've learned from EMPAVELI, now that EMPAVELI has been working with transplants, is that at a lot of these centers, you have to be on protocol. I bring up protocol because protocols can take time, which is why we've already hired a medical team that has already visited 100 transplant centers, and they're already examining how to get on the protocol as quickly as possible once an approval is in hand. So as you look at the ramp, you're going to have to know that a couple of months out of the gate, some centers will start right away. Others will gradually come on. You're also going to have a bolus of patients already sitting in that transplant center. Typically, transplant patients stay with the transplant center for approximately a year. They return to their general nephrologists. General nephrologists are actually very good at monitoring for AMR. And they're also pretty good at already referring them into the transplant centers. So that system, though it isn't perfect, is already in place; so we know that right out of the gate we'll have a good set of patients at launch, and we're already currently working on the second tranche of patients that you would get after that bolus appears. So when we examine the top 100 centers, as I mentioned, at this point it's largely about education and grasping the protocols, and how fast we can get things going. Then for general NAVs, it comes down to how consistently they diagnose and conduct surveillance for AMR, and making sure they refer those patients sooner rather than later. Now, alongside that ramp, clearly we receive many questions regarding price; and you've likely observed what has been occurring in the market with IGAN, but our belief is that pricing will mirror the substantial value Fels is going to deliver for patients; and when you consider pricing for the product, also bear in mind the dosing of felzartamab. For instance, in AMR, during year 1, they will receive 12 doses. In year 2, they receive 6.5 doses; so you're also going to witness, similar to what we saw with SPINRAZA, that in the first year we were going to capture actually a fair amount of value for the patients as they drop to 6.5 doses in the second year. Beyond AMR, you have MDI. Now we regard MDI as incremental to AMR rather than a distinct commercial market. And now that we've done additional work on it, we can see that physicians are also looking at MBI. We believe this provides an additional 30% on top of that AMR patient population. So the largest opportunity for MBI will be to raise more awareness outside of < >. At present, KMs understand it well, but it's currently an underappreciated disease that we have some time to work on, though we've already begun those conversations.

Brian Abrahams

analyst
#12

Congratulations on the quarter. Perhaps I could ask Priya one more question regarding < >. I realize you've already walked us through part of this, but could you go into a bit more detail about how you see the baseline characteristics of the patients enrolled in TOPAZ-1 and 2 relative to the Phase II study, especially when it comes to interferon gene signatures?

Priya Singhal

executive
#13

Thank you, Brian. Taking a step back, my view is that interferon gene signature is something we expect to be high among SLE patients generally, and the literature backs that up as well. And truly, looking at baseline, we aren't aware of any differences between LiLAC and TOPAZ-1 and 2 when it comes to interferon gene signature. We will only find out later, once we examine the data, and these are areas we will be looking at closely.

Umer Raffat

analyst
#14

I'd also like to zero in on the SLE trial. Priya, looking at the Phase II data, one thing that really jumps out regarding the SRI-4 endpoint is that the whole delta — that full separation from placebo — came from basically a single subcomponent, which is led to once again. I'm certain you know that well too. How do you view the relevance of that finding as we head toward Phase III? Do you still expect it to be what drives it, or will additional components contribute too? And would you be able to pull data across both studies by the interferon high subgroup, if that's needed, since other companies in the space are commenting on that even in a scenario where one of the trials doesn't hit stats.

Priya Singhal

executive
#15

Yes. Thanks, Umer. I think, just taking a step back, we believe SRI-4 is the correct primary end point — that was our view when we designed the trial, given our focus on skin and joints and how it measures outcomes. So from that angle, we think that's right. Yes, I think once we see the data we'll have the opportunity to decide how we might pull and which aspects of these trials should be combined. And I think that will be data dependent and also dependent on conversations and discussions with regulators. So we wait to see the data. And of course, we plan ahead of that, but we wait to see the data now.

Salveen Richter

analyst
#16

Could you break down how much of the growth in commercial injections for SYFOVRE stems from reducing complimentary drug supply versus actual demand? And regarding the education efforts, as you focus on bringing down the discontinuation rate, it would help to hear what's connecting with physicians and patients, and where the barriers that remain lie.

Alisha Alaimo

executive
#17

Salveen, Alisha here. Thanks for asking. The team has truly done a remarkable job bringing down the free goods on this product. But that's been the case all along — from the moment we completed the acquisition. So we spotted that as an area with room for improvement even before we had acquired them. The team has handled that well. Turning to commercial injection growth, particularly the year-over-year figure, we connect that to the SYFOVRE team's strong work in lifting overall sentiment around treating GA and slowing lesion progression. In fact, I attended one of their big conferences, where I spoke with numerous PE firms and retina specialists, and they report that sentiment has improved considerably across the board. They're now more open to receiving additional injections, so these commercial injections are also coming from a growing number of HCPs joining and from deeper prescribing as well. Now, I've said before that the discounts after that initial month of injection are quite high; we're just now implementing many of those tactics to try to address that. And I have to say the biggest problem is this: when I speak with a physician or we conduct patient market research, patients aren't really told what to expect when they receive the injection. And when you look at wet AMD — incidentally, 40% of GA patients have wet AMD too — those people expect everything to clear up immediately. The idea of slowing progression isn't something they grasp; so after receiving the injection, they think, oh, that isn't working, and they don't return. That means there's an education component we're putting in place — for patients, and even for office staff, plus really having conversations with the physicians. Retina specialists, when you speak with them, aren't actually aware that these patients stopped treatment at month one. So once education is in place, I really think we'll see a pretty nice lift as they begin teaching patients. The other piece of this will center on—I've said this previously—now that we've had a very strong quarter and not only increased revenue but also increased volume, we believe DTC will serve as a great strategic lever. We noticed that when they ran DTC for SYFOVRE some time ago—and frankly, the outcomes were quite impressive; we saw a clear impact on patients who came in requesting the product. Then, for whatever reason, they naturally stopped it. But since they're now part of Biogen, we chose to relaunch that initiative. We've got a concept ready. We ran it by Chris. We think it'll be a highly effective DTC campaign, we're aiming to roll it out next year, and we genuinely believe we'll draw even more patients into physicians' offices.

Michael Yee

analyst
#18

Perhaps a question about the cutaneous lupus data readout coming in the first half. Chris, could you comment beforehand on how confident you are in that indication for that program relative to the systemic indications, which I think people would see as carrying somewhat higher risk, and also thinking about either the target, which differs from dapolizumab, for instance, and just your overall confidence in that study? I know you value your < > 1 study here versus the systemic 2 studies; so I just wanted to think about how you're framing the cutaneous readout.

Priya Singhal

executive
#19

Yes. Thanks, Michael. I think simply taking a step back, we believe SLE and CLE both represent areas of high unmet need. We also believe that the mechanism of action, as observed in — from LiLAC in Phase II, shows the drug has activity in both forms of the disease. I think simply taking a step back, it's really too close now, and I don't want to speculate, so I'm not going to really discuss confidence. We know systemic lupus is generally more heterogeneous. So I think that's the area I mentioned earlier as well as to what strategies we put in to really address the variability that we see. Turning to cutaneous lupus. This is obviously a visible condition. It's easier to kind of visualize and see impact. So I'll just stop there; but I think, overall, we believe both are important, high unmet needs, and we're going to see data in both these indications, and we have seen data in Phase II. So we'll wait to see what we get in Phase III.

Alexandria Hammond

analyst
#20

On SPINRAZA high dose, what conversion rates are you observing in the U.S., and where do you think those will level off at steady state? And secondly, does that make you feel confident about the commercial picture for salinersen, assuming a positive Phase III readout, I believe, in '28?

Alisha Alaimo

executive
#21

Thanks, Alex. Alisha here. We're really happy with the way SPINRAZA high dose is doing. In fact, anyone tracking rare disease launch benchmarks is aware that SPINRAZA 12 mg was at one point the benchmark for the biggest rare disease launch ever. And as of today, that title in fact goes to SPINRAZA high dose. We also think it has set a fresh standard for efficacy now too. The thing that truly sets this community apart is, first of all, their awareness of every trial that comes out — they know each and every physician, and whenever they want something, they go and ask for it. A great deal of what you're observing with high-dose SPINRAZA is really community-driven, with patients pulling for it and requesting it from their doctors. And by the way, this isn't only happening in the U.S. — I want to call out the other two regions, Europe and ex U.S. and Europe, where we're seeing similar results across the board with SPINRAZA, and every one of the launches across the board has been a success. If you look at the start forms — basically they show the intent to obtain a prescription for the patient — by the close of Q3, 70% of the 12 mg patients have a start form submitted, which is very high. We also know that 50% have been dosed with the product by now, which means quite a few of these patients have been pulled forward. Obviously, we aren't in Q4 yet. But as you can imagine, even more of those patients will land in Q4. That means next year there won't be as many patients receiving that onetime benefit of the 90,000 that you're seeing this year with every transition dose. Another pattern we're observing, and again this holds in every region, is that some patients are returning—they had been receiving SPINRAZA, moved to a rival product, and what we term a switch back is occurring. A share of patients, then, have been coming back to us. In addition, some patients are being dosed either shortly before older generations or following Zolgensma. That leaves an opportunity we'll be examining in the coming year, both in switchbacks and in new patients, extending past the transitions. That said, the aim behind high-dose SPINRAZA is to keep the patients we already have, particularly as we get closer to a possible launch of salonersen—and I should note that the community is already aware of salinersen, with patients asking about it. We also believe that, if it were to receive approval, it would be a genuinely substantial commercial opportunity for us.

Paul Matteis

analyst
#22

I'd like to ask something about zuvenorsen before we get data next year. Could you discuss what you've done to build confidence around pricing that drug at a premium outside the U.S., where antiepileptic medicines tend to be fairly inexpensive? And on the thesis side, how central is it to actually demonstrate a static effect on cognition in the Phase III DRIVE study?

Tim Power

executive
#23

Yes, Paul, I believe there's an opportunity to reprice this market. And the true differentiation, as you mentioned, is the impact on cognition. So as we — I think we've discussed before that this is an addressable market of at least $1 billion outside the U.S. And clearly, we need to see the Phase III results. But I think if they replicate the Phase II. And I do believe we have a fairly compelling proposition to bring to payers in Europe.

Evan Seigerman

analyst
#24

Congrats again on the truly solid progress. I'd like to ask about < >, especially given the growth we're seeing in that area. Out in the field, what feedback are you hearing from patients and from providers about iClick? Are they — is it producing the uptake you'd hoped for? And looking toward next year, what more can you do to broaden the market and sustain the growth?

Alisha Alaimo

executive
#25

Thanks, Evan; it's Alisha here. I'm really glad you raised the question of what can be < >. First, though, I'd like to cover Part D, if that's alright, since those were the questions we fielded quite a lot over the past couple of quarters; and if you've had a chance to review the formularies that have been published, you'll notice that in Part D, as Robin also noted, we have at least 50% coverage, which I have to say, at this point in time, particularly after IRA, Part D plans have been rather restrictive. So we're quite happy with where we stand in Part D. Also bear in mind that open enrollment is happening right now. So I can't really give you the total lives, because 30% are still in flux; so while we know of 50% at this point, we do expect that we'll have greater than 30% as we head into January of next year, which beats what we had anticipated for next year. So that's really good news. Now, when you look at how iClick is performing, I think what you'll find is that it's genuinely reframing the convenience conversation. And this is actually a pivotal moment for LAC to become more accessible and simpler for patients to start; and over the longer term, as we've said previously, we believe iClick is 1 of the only things in our portfolio that will actually expand the market overall for the whole class. Now if you look at DBD data, which I know many of you purchase, it doesn't have a great capture rate. It will show really astronomical numbers for how they capture it. I'd say, don't look at iClick eyes for the DBD data. But when you do examine how it's performing in market and you compare it with, say, the LEC IV launch or Casinla, iClick Eye is outpacing the LECIV launch by 3.5 and Kasumi by 6 times. Now these are early days. And so you will see that some of that is going to be orders going into certain IDNs and maybe embolus of patients. However, the interesting thing that we're seeing that we haven't seen before, I click, of course, the majority you'll see come from Lacombe writers and also dual writers. However, what we're seeing now is writers who had never previously prescribed in AAT, had never written cast, had never written like IV—they're now writing iClick. We're also seeing physicians whose only prior experience was writing Cassia right click. So you're beginning to observe a real shift in the dynamics, particularly in regions with long drive times. On the West Coast, for instance, we're seeing the quickest uptake, where there's genuinely a great deal of space and geography at play. The convenience factor is also coming into play. That said, I believe that this year, at this moment, it's outpacing what our were. It's still early days. And when you look ahead to next year, I think we're going to find that subcu has truly become a tremendous option for patients and physicians alike. And the fact that physicians who have never written in AAT before are now prescribing it is a very good signal to us that this could be very promising for next year and the years beyond.

Geoffrey Meacham

analyst
#26

Now, to your question — zooming out a bit, Chris. The comeback in top-line growth looks like it's built to last, and there's a healthy amount of interest in the pipeline. What I'm really getting at is this: as you consider putting capital to work, where does the priority lie? Could it be pushing fultartinib development further, for instance, or putting more commercial money behind SYFOVRE or EMPAVELI, Pavel, or remaining aggressive in < >. I'd just like to hear your read on how the internal versus external balance will shape up going forward.

Christopher Viehbacher

executive
#27

0 Yes. Thanks. Well, obviously we can't say anything definitive until the clinical trial results come in, but we're looking at those 10 Phase III launches, or 5 NME launches. And remember, part of the thinking behind the Apellis acquisition was to get a commercial team for felzartamab; that doesn't mean we wouldn't want to build it out further, but it won't be the kind of investment where we're starting from zero in that space. Lupus, I'd expect, is going to require substantial investment and a lot of education; zorvinersen, I think, addresses a really limited population that will look much more like a rare disease, and salinersen also comes in behind the SPINRAZA. As we expand the business, our goal is plainly to put money into commercial efforts and also keep funding R&D. That said, investors have been waiting quite a while for us to grow, in my view. So we'll pay close attention to various ratios and to how much we spend relative to improving our bottom line. But actually, I believe we can handle all of it. So we will certainly invest in our continued success. On the external side, as I mentioned before, I think our real focus is the early stage. That's when bringing new assets into a company uses capital most efficiently. I've never liked the idea of acquiring assets at a later stage, since a fair amount of risk still comes with that. If our pipeline performs reasonably well — though we'll have to wait and see the results — there's good potential for the company simply to grow for the foreseeable future, which is why our focus is really on growth into the next decade. That gives us time to develop the assets. So we're looking heavily at D.C. through Phase Ib, which I'd say is probably our sweet spot. Over the past three years, we've taken a pretty deliberate approach to M&A—examining every possibility and screening each one. These days we're less deliberate about it, though we can still act opportunistically. Should a target come along that strengthens one of our current franchises—and one concern I keep firmly in mind is distraction—we'd consider it. Biogen is changing dramatically. Four years back, neurologists were essentially our only call point. Today, our regional teams concentrate on retina specialists, nephrologists, and transplant nephrologists; in lupus, dermatologists and rheumatologists will be our targets; and with reserversen, epileptologists are potentially in view. That's essentially how we've expanded the whole commercial organization. A substantial amount of talent is being drawn from the ranks of our 150 most senior leaders — about 50% of those individuals have joined within the past three years. That adds up to a tremendous degree of transformation, and my sense is we sincerely need the capacity to take that in, fully seize the opportunities ahead of us, and avoid overextending ourselves. That's how I see the situation.

David Amsellem

analyst
#28

I'd like to raise a commercialization question about lidafilimab, and I know that may be getting ahead of ourselves here, what with the data readouts still to come. But I wanted to hear your thinking on how you're sizing the CLE opportunity versus the SLE opportunity, keeping in mind that a lot of patients with cutaneous disease also have systemic disease, even though no therapies are approved for cutaneous disease or it's a much — there's a shortage of treatment options, obviously, in that space. So how are you approaching the sizing of the 2 opportunities? And how separate do you consider these 2 opportunities to be?

Alisha Alaimo

executive
#29

Thank you. This is Alisha. I guess the main thing is that we treat these as two distinct opportunities. With CLE, you've got 250,000 patients who have CLE only, and for SLE there are 300,000 patients with SLE only, plus another 50,000 who have both conditions. That puts CLE at 300,000 patients in total. On the CLE side, as the team frames it, CLE changes a patient's life, while SLE is life ending. So those are really different markets; in CLE, under 5% are actually treated, unlike SLE, which sits at roughly 30% as you're aware. There is a split across rheumatology and dermatology with only 1/3 of these patients being managed by dermatology; and what ends up happening with the patients is that specialists will refer to each other. So the patients then get left waiting while the damage continues to progress because they sort of get stuck in the middle. If you talk to a physician for CLE about what they want to happen for a product. So if they were to prescribe because right now, they don't prescribe the biologics for this disease, they really want to make sure the drug works, it's safe, and fairly easy to use. What they're looking for is minimal monitoring, plus the ability to get at the therapy fast, so patient services matter a great deal in this disease state. From the patient's perspective, the aim is simply to see some kind of visible improvement—this happens before permanent scarring sets in, before hair loss occurs, or before there's truly major disfigurement, particularly on the face. So in this area, our emphasis is more on getting the dermatologist to treat, whereas with SLE, rheumatologists are already treating. Our goal is to ensure dermatologists feel empowered to treat patients early and urgently, and we need to make this diagnosis simpler for them so patients don't suffer any of those horrible irreversible damages they discuss so often, and then speed up adoption of the higher efficacy treatment. What we don't want to see in dermatology, like what you see in rheumatology, is them waiting; and we believe that because derms already prescribe biologics in other parts of their business. And once they understand how these products work and how to access them, and once we're on formulary, they'll wind up picking them up at a fairly good clip. So our view of it is a little bit different from how we view SLE.

Danielle Brill Bongero

analyst
#30

Perhaps I could actually pose one about IgAN. So given that the FDA is now receptive to a 1-year eGFR endpoint, and with the April agents becoming standard of care, are you rethinking the design, including the 2 years on placebo? And then if you were to move to a 1-year eGFR endpoint, would the trial still have adequate power?

Priya Singhal

executive
#31

Thank you, Danielle. Taking a step back, I think we have evaluated that while proteinuria continues to be a highly relevant marker of disease activity, eGFR really offers a more clinically meaningful measure of long-term renal outcomes. So we are in fact planning to remain current and ahead by updating our primary endpoint to eGFR, to reflect the evolving evidence base and the growing importance of directly assessing kidney function and IDM; so we're going to — we're already beginning this change. We believe that this change will align the program with the current treatment landscape as well as regulatory expectations, and will let us more clearly characterize the potential benefit of < >. But beyond that, I would say we continue to hear and receive reinforcement of the fact that the drug holiday and the ability for patients to be off drug while remaining in remission is very important. So this continues to be a very important differentiator for felzartamab in IgAN. So we'll continue to keep both of those aspects in mind as we reflect these updates.

Mohit Bansal

analyst
#32

Congratulations on the progress. I'm just trying to get my head around the guidance a bit here. If I run a simple calculation of, say, 5% growth — assuming that's what mid-single-digit growth means — and then subtract the 9 months of sales, it looks like you're modeling a pretty big sequential drop in the fourth quarter versus the third quarter. I get to roughly $30 million, but what are we missing? Because that seems like a lot of decline from the third quarter to the fourth quarter. So I'd like to understand how you're thinking about it.

Robin Kramer

executive
#33

Yes. Thank you for the question. Looking at how Q3 turned out, as I mentioned earlier, revenue got a meaningful boost—Alisha highlighted the SpinHD conversion rate—so conversions we'd anticipated for Q4 ended up landing in Q3, plus there were inventory effects tied to < > and a few other products, which together gave us that favorable top-line shift. The revised guidance and where we ended up reflect that. You may remember that on the prior earnings call, we had already lifted our guidance. For this quarter, we are raising the bottom of our guidance range. The main reason is the appellate integration and how well it has gone—both on the revenue side and because we captured the expense synergies sooner than expected.

Andrew Tai

analyst
#34

Regarding SLE, assuming both litafilumab and DAPI turn out successful — could you remind us how those two drugs would sit relative to one another, and also against the competing drugs out there? And what makes us think either one could serve as a first-line therapy ahead of standard of care?

Alisha Alaimo

executive
#35

This is Alisha, and I'll handle that question. We're currently working through positioning for both products, particularly if we're lucky enough to get both approved — which, incidentally, hands us 2 shots on goal for SLE, something we also consider critically imprudent; we also think they may bring some differentiation. For instance, we know DAP has demonstrated improvement in fatigue, and we know that fatigue ranks among the major complaints from SLE patients. As for first line, sure, there will be plenty of competitors, but how the data reads out will matter, and I believe success in lupus will be directly correlated with how you address the barriers these physicians and patients are up against. So it will also be data dependent. That said, what the current organizations have not managed to do is actually address the barriers behind why they're waiting, as Chris mentioned, waiting on prescribing products. Patients haven't been activated to go in and ask for these products. And so I also think that with the commercial powerhouse Biogen has been able to create over the last 7 years with all of the 7 launches that we've had, we also believe that commercialization — how you market the product — will become just as important. And so it remains to be seen, but with 2 shots on goal, I think we're going to be able to compete to win pretty well.

Christopher Viehbacher

executive
#36

And once again, I'd say Biogen brings a great deal of experience to this. In the MS portfolio, for example, we've had several products, and we've been able to pinpoint precisely which patients benefit from which product at the right moment. So I believe that will carry over to lupus as well, assuming we're lucky enough to have both of those products.

Marc Goodman

analyst
#37

I did catch your remarks on Sky Claris inventory, but could you expand a little on what you meant by growth? What sort of growth are we seeing among U.S. patients, and give us some of the overseas dynamics, since it's somewhat country by country — what's launched and what's still pending, what's expanding, what's been reimbursed? Just a bit more detail there.

Alisha Alaimo

executive
#38

This is Alisha. I'll take the first part of that question, especially on the U.S. Our 2026 performance with Sky Claris is encouraging to us, particularly as we continue growing year-over-year. We do expect that growth to carry on going forward. A couple of dynamics are at play, especially within our organization. First and foremost, I think the patient finding tools we have now, the AI predicting where these patients are, and the way the teams collaborate to find them have really reached a level of 1 of the most efficient models I have seen; so they've done a very good job finding those patients and getting them on product. The other thing the team has done very well is that in the beginning, we had a very high discount rate off of Sky Claris. At this point it sits at a far smaller share than in earlier periods, and as we go through the remainder of the year, those discounts appear to be holding steady. We therefore expect further year-over-year gains, though the bigger point is that expanding into pediatrics gives us the next substantial opening for a turning point in growth down the road.

Robin Kramer

executive
#39

And — Robin here, and I'll address the U.S. dynamics. From a demand standpoint, we anticipate that growth across the rest of this year and into next year will mainly come from SkyClaris continuing to expand worldwide. We keep launching in additional jurisdictions, including the recent approval in Brazil. So that's where future demand-driven growth is concentrated.

Tim Power

executive
#40

Appreciate that, Robin, and thank you all for joining us today. Should any additional questions come up, feel free to contact the IR team here at Biogen. Thanks.

Operator

operator
#41

This concludes today's call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.